Navigation Links
New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
Date:11/9/2010

atients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral and other infections due to opportunistic pathogens.

  • The risks and benefits of treatment with certolizumab pegol should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with certolizumab pegol, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which certolizumab pegol is a member. Certolizumab pegol is not indicated for use in pediatric patients.Serious and sometimes fatal infection due to bacterial, mycobacterial, invasive fungal, viral or other opportunistic pathogens has been reported in patients receiving TNF-blocking agents. Among opportunistic infections, tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis were the most common.  Treatment with certolizumab pegol should not be initiated in patients with an active infection, including clinically important localized infections.  Certolizumab pegol should be discontinued if a patient develops a serious infection or sepsis.  Patients who develop a new infection during treatment with certolizumab pegol should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for immunocompromised patients, and appropriate antimicrobial therapy should be initiated.  Appropriate empiric antifungal therapy should also be considered while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are ende
    '/>"/>

    SOURCE UCB
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
    2. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
    3. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
    4. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
    5. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
    6. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
    7. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
    8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
    9. Marken Rapidly Responds to Global Supply Chain Security Measures
    10. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
    11. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
    (Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
    (Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
    Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
    ... and IRVINE, Calif., May 6, 2011 CryoLife, Inc. ... device and cardiovascular tissue processing company, today announced the ... through its wholly owned subsidiary CL Falcon, Inc., for ... ("Cardiogenesis") (OTCQB: CGCP).  The tender offer expired at 12:00 ...
    ... The Female Health Company (NASDAQ-CM: FHCO) today announced ... Comercio (Semina), was successful in a public tender to ... to 20 million FC2 Female Condoms.  The contract is ... will be determined at the Ministry of Health,s discretion. ...
    Cached Medicine Technology:CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 2CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 3CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 4CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 5CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 6The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3
    (Date:8/30/2014)... 2014 Hands On Mobile ... offers the complete spa experience combining elegant decor, ... the most important ingredient of all, states Marla ... pro's! People will enjoy the get-away feel, without ... website reads, "Step into the spacious, luxurious spa ...
    (Date:8/30/2014)... 2014 Daily Gossip magazine reveals in ... and panic attacks under control with a simple and ... describes this new method as an anxiety recovery ... and overcome general anxiety related disorders. , What ... fact that it can be accessed by users from ...
    (Date:8/30/2014)... (PRWEB) August 30, 2014 The ... Nutrition and Pharameuticals. Nutraceuticals is a source of ... ingredients from natural food sources. Nutraceutical ingredients have ... to the human body. Nutraceutical health products include ... fortified foods and more. Although nature is the ...
    (Date:8/30/2014)... Hicksville, NY (PRWEB) August 30, 2014 ... Organizations throughout the planet has been one of ... in order to create a positive impact around ... aesthetics and staffed with top trained executives and ... millions of people worldwide. Vital statistics demonstrate ...
    (Date:8/30/2014)... TX (PRWEB) August 30, 2014 ... Disruptor Industry, 2009-2019 is a professional and in-depth ... industry. The report firstly reviews the basic information ... manufacturing technology. The report then explores global and ... product specification, capacity, Production value, and market share ...
    Breaking Medicine News(10 mins):Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4
    ... The earliest known case of coronary artery disease has been ... lived between 1580 and 1550 B.C., and died in her ... scans found that this wasn,t a unique case. About 45 ... an accumulation of plaque in arteries. The findings ...
    ... a genetic characteristic of metastatic prostate cancer that defines ... published in Cancer Discovery , the newest journal ... debut at the AACR 102nd Annual Meeting 2011, held ... an investigator of the Howard Hughes Medical Institute and ...
    ... laboratory and epidemiologic data to find that men using the ... prostate cancer. The scientists say further research about the ... ones that work the same way, to treat the cancer. ... for centuries in folk medicine and for decades to treat ...
    ... bladder cancer risk and to the length of protective caps ... of Texas MD Anderson Cancer Center reported today at the ... telomeres, guard against chromosomal damage and genomic instability that can ... single point of variation in the genome strongly associated with ...
    ... use has been linked to thicker arteries, possibly contributing to ... of twin veterans. The data is being presented Tuesday, April ... Orleans. Depression can heighten the risk for heart disease, ... is separate and independent from depression itself, says first author ...
    ... hedgehog pathway inhibitor demonstrated efficacy in preventing and treating ... syndrome, a rare inheritable disease, according to Phase II ... held April 2-6. In 1996, Ervin Epstein Jr., ... Institute, and colleagues identified the site of the mutation ...
    Cached Medicine News:Health News:Mummies Show Heart Disease Is an Ancient Problem 2Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 2Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 3Health News:Genetic variation cuts bladder cancer risk, protects chromosome tips 2Health News:Genetic variation cuts bladder cancer risk, protects chromosome tips 3Health News:Antidepressants linked to thicker arteries 2Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 2Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 3
    Used for stone manipulation and removal in the urinary tract. The hollow shaft allows protected delivery of a laser fiber to an entrapped stone for fragmentation of the stone. Supplied sterile in pee...
    ... Tipless Design, ZeroTip basket features ... negotiation and close stone approximation., Flexible ... deflection for efficient retrieval of calyceal ... passed through a 3.6Fr working channel, ...
    ... Tip 12 Inch , 20 inch,PVC, Length ... Available in 3,4,5 6Fr. These top quality ... flexible polymer material and have standard screw ... They are manufactured to the highest standards. ...
    Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)...
    Medicine Products: